KPTI - Karyopharm Is Trading At A Discount After Recent Additional Xpovio Approval
Karyopharm (KPTI) is a commercial-stage pharma company that already markets its leading compound, Xpovio or selinexor, in 2 different cancer indications. Karyopharm fits the model I look for of companies with a novel technology platform that’s already clinically-validated and is trading at a substantial discount to fair value. In this article, I provide an overall view of the company as well as my thoughts on Karyopharm’s valuation.
Novel Pipeline of SINE Compounds with 2 Marketed Indications and Lots of Pipeline Potential
Nearly all of Karyopharm’s approved and pipeline products are considered to be